Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Koo on Degarelix for the Treatment of Prostate Cancer

Alec S. Koo, MD
Published: Tuesday, Nov 24, 2015



Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.

Degarelix is an LHRH antagonist that, both functionally and theoretically, has advantages over agonists. It also suppresses testosterone levels quicker and more efficiently, Koo explains.

Usually, when patients begin on agonists, an initial flare occurs and testosterone levels take longer to drop, Koo says. Degarelix should be administered when patients first start on LHRH therapy.


Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.

Degarelix is an LHRH antagonist that, both functionally and theoretically, has advantages over agonists. It also suppresses testosterone levels quicker and more efficiently, Koo explains.

Usually, when patients begin on agonists, an initial flare occurs and testosterone levels take longer to drop, Koo says. Degarelix should be administered when patients first start on LHRH therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x